Univest
Univest
  • Markets
  • Akums Drugs Analyst Review 2027: CDMO Engine Lifts Profit 168%, Stock Runs Past Older Targets

    • November 18, 2026
    • Posted by: Chaitanya Auti
    • Category: Market
    No Comments
    Akums Drugs Analyst Review 2027: CDMO Engine Lifts Profit 168%, Stock Runs Past Older Targets

    Akums Drugs and Pharmaceuticals grew Q2 FY27 revenue about 32% and profit about 168% as CDMO margins jumped to 15.1%. The stock now trades above earlier ICICI Securities and Citi targets. We review results, analyst views, valuation and risks for 2027.

    read more